References
- Bouchardy C, Fioretta G, Rapiti E, et al (2008). Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer, 123, 421-9. https://doi.org/10.1002/ijc.23520
- Brown CT, O'Flynn E, van der Meulen J, et al (2003). The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int, 91, 30-2. https://doi.org/10.1046/j.1464-410X.2003.04013.x
-
Franlund M, Carlsson S, Stranne J, Aus G, Hugosson J (2012). The absence of voiding symptoms in men with a prostatespecific antigen (PSA) concentration of
${\geq}$ 3.0ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg randomized screening trial. BJU Int, 110, 638-43. https://doi.org/10.1111/j.1464-410X.2012.10962.x - Gretzer MB, Partin AW (2003). PSA markers in prostate cancer detection. Urol Clin North Am, 30, 677-86. https://doi.org/10.1016/S0094-0143(03)00057-0
- Hochberg DA, Armenakas NA, Fracchia JA (2000). Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate, 45, 315-9. https://doi.org/10.1002/1097-0045(20001201)45:4<315::AID-PROS5>3.0.CO;2-2
- International Union Against Cancer (1997). Urologic Tumors: Prostate. In 'TNM Classification of Malignant Tumours. 5th ed.' Eds Sobin LH and Wittekind CH. John Wiley & Sons, New York pp170-3
- Ito K (2009). Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives. Int J Urol, 16, 458-64. https://doi.org/10.1111/j.1442-2042.2009.02293.x
- Ito M, Masuda H, Kawakami S, et al (2013). Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen <10ng/ml and non-suspicious digital rectal examination. Int J Urol, 20, 1163-8. https://doi.org/10.1111/iju.12141
- Kash DP, Lal M, Hashmi H, Mubarak M (2014). Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. Asian Pac J Cancer Prev, 15, 3087-91. https://doi.org/10.7314/APJCP.2014.15.7.3087
- Kitagawa Y, Mizokami A, Nakashima K, et al (2011). Clinical outcomes of prostate cancer patients detected by prostatespecific antigen-based population screening in Kanazawa city, Japan. Int J Urol, 18, 592-6. https://doi.org/10.1111/j.1442-2042.2011.02796.x
- Kitagawa Y, Mizokami A, Namiki M (2013). Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. Prostate Int, 1, 65-8. https://doi.org/10.12954/PI.12017
- Kobori Y, Kitagawa Y, Mizokami A, et al (2008). Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0ng/ml as a criterion. Int J Clin Oncol, 13, 229-32. https://doi.org/10.1007/s10147-007-0742-2
- Kubota Y, Ito K, Imai K, et al (2002). Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate, 50, 262-9. https://doi.org/10.1002/pros.10057
- Kwon HT, Ma GX, Gold RS, Atkinson NL, Wang MQ (2013). Primary care physician's cancer screening recommendation practices and perceptions of cancer risk of Asian Americans. Asian Pac J Cancer Prev, 14, 1999-2004. https://doi.org/10.7314/APJCP.2013.14.3.1999
- Matsubara A, Yasumoto H, Teishima J, et al (2006). Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int J Urol, 13, 1098-102. https://doi.org/10.1111/j.1442-2042.2006.01504.x
- Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al (2003). Prostate-specific antigen as estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol, 44, 695-700. https://doi.org/10.1016/S0302-2838(03)00384-1
- Okihara K, Kitamura K, Okada K, et al (2008). Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol, 15, 156-61. https://doi.org/10.1111/j.1442-2042.2007.01957.x
- Schulman CC, Kirby R, Fitzpatrick JM (2003). Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol, 44, 294-302. https://doi.org/10.1016/S0302-2838(03)00200-8
- Shin S, Kim YH, Hwang JS, et al (2014). Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea. Asian Pac J Cancer Prev, 15, 3383-9. https://doi.org/10.7314/APJCP.2014.15.8.3383
- Verim L, Yildirim A, Basok EK, et al (2013). Impact of PSA and DRE on histologic findings at prostate biopsy in Turkish men over 75 years of age. Asian Pac J Cancer Prev, 14, 6085-8. https://doi.org/10.7314/APJCP.2013.14.10.6085
- Young JM, Muscatello DJ, Ward JE (2000). Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int, 85, 1037-48. https://doi.org/10.1046/j.1464-410x.2000.00659.x
- Zheng XY, Zhang P, Xie LP, et al (2012). Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSADV) for early detection of prostate cancer in Chinese men. Asian Pac J Cancer Prev, 13, 5529-33. https://doi.org/10.7314/APJCP.2012.13.11.5529